The purpose of the Informatics Core Facility in the MSKCC SPORE in Prostate Cancer is to provide information technology and data modeling that will facilitate the translation of scientific discovery to clinical care. Although this process may occur in a variety of mechanisms, certain activities dominate. Because markers of disease may be discovered, this Core Facility would be needed in helping to define their clinical role. Groups of markers may need optimal assembly for the purposes of clinical prediction. Complex clinical decisions may require formal analysis. Large amounts of data may need thoughtful simplification and processing. Limited resources may need rational allocation. Each of these activities may utilize the Informatics Core Facility; it is, there fore, important that this Facility provides a quality program of innovative collaborations supporting basic and clinical research. Moreover, members of the Core Facility will function as colleagues with SPORE scientists and clinicians throughout the research process.
Specific Aims : l) To perform detailed prognostic modeling, such as nomogram development. 2) To develop decision analytic systems which address important clinical problems. 3) To provide statistical analysis of data, to address hypothesis of interest, from personnel dedicated to prostate cancer. 4) To ensure rational resource allocation by statistical power analysis for all requests of specimens and mice. 5) To provide investigators with high-quality datasets by: a. extracting patient data from various Memorial Sloan-Kettering Cancer Center databases b. actively following patients, who do not return to MSKCC, through letters and phone calls, and storing this data in databases we develop. c. applying sophisticated algorithms to consistently select and compute critical dataset fields (e.g., failure dates). d. working with institutional database developers to ensure that prostate cancer data are being stored and collected in a manner conducive to both research and clinical care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA092629-02S1
Application #
6664524
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-10
Project End
2003-08-31
Budget Start
Budget End
Support Year
2
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Han, SoHyun; Stoyanova, Radka; Lee, Hansol et al. (2018) Automation of pattern recognition analysis of dynamic contrast-enhanced MRI data to characterize intratumoral vascular heterogeneity. Magn Reson Med 79:1736-1744
Kinsella, Netty; Helleman, Jozien; Bruinsma, Sophie et al. (2018) Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Transl Androl Urol 7:83-97
Vickers, Andrew J; Steineck, Gunnar (2018) Prognosis, Effect Modification, and Mediation. Eur Urol 74:243-245
Hieronymus, Haley; Murali, Rajmohan; Tin, Amy et al. (2018) Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. Elife 7:
Scher, Howard I; Graf, Ryon P; Schreiber, Nicole A et al. (2018) Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer. JAMA Oncol 4:1179-1186
Bielski, Craig M; Zehir, Ahmet; Penson, Alexander V et al. (2018) Genome doubling shapes the evolution and prognosis of advanced cancers. Nat Genet 50:1189-1195
Luo, Jun; Attard, Gerhardt; Balk, Steven P et al. (2018) Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol 73:715-723
Settleman, Jeffrey; Sawyers, Charles L; Hunter, Tony (2018) Challenges in validating candidate therapeutic targets in cancer. Elife 7:
Miyazawa, Miki; Subbaramaiah, Kotha; Bhardwaj, Priya et al. (2018) Pioglitazone Inhibits Periprostatic White Adipose Tissue Inflammation in Obese Mice. Cancer Prev Res (Phila) 11:215-226
Graham, Laura; Banda, Kalyan; Torres, Alba et al. (2018) A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Invest New Drugs 36:458-467

Showing the most recent 10 out of 505 publications